Core Viewpoint - Zhaoke Ophthalmology-B (06622) has expanded its partnership with AFT Pharmaceuticals Limited for the commercialization of BRIMOCHOL™ PF in Singapore and established a strategic partnership with Santen Pharmaceutical Co., Ltd. for commercialization in Vietnam, indicating a strong commitment to global expansion [1] Group 1: Partnerships and Agreements - The company has granted exclusive distribution rights for BRIMOCHOL™ PF to AFT in Singapore and to Santen in Vietnam, which includes rights for registration, import, promotion, distribution, marketing, and sales in these markets [1] - AFT and Santen become the seventh and eighth commercialization partners for BRIMOCHOL™ PF, respectively, highlighting the company's strategy to broaden its market reach [1] Group 2: Product Information - BRIMOCHOL™ PF is a potential therapy aimed at correcting near vision loss due to presbyopia, representing a core asset acquired through a partnership with Tenpoint Therapeutics, Ltd. [1]
港股异动 | 兆科眼科-B(06622)涨超5% 已扩大与AFT的伙伴协议 于新加坡商业化BRIMOCHOL™ PF